EcoDrugPlus

Estrogen-Related Receptor Gamma A

Ensembl ID : ENSLCRG00005019639
Gene Symbol: ESRRGA
3 Cross references
198 Possible Orthologues:

Exportin 1

Ensembl ID : ENSLCRG00005000379
Gene Symbol: XPO1
3 Cross references
224 Possible Orthologues:

Exportin 1

Ensembl ID : ENSLCRG00005005671
Gene Symbol: XPO1
3 Cross references
211 Possible Orthologues:

Farnesyl Diphosphate Synthase (Farnesyl Pyrophosphate Synthetase, Dimethylallyltranstransferase, Geranyltranstransferase)

Ensembl ID : ENSLCRG00005008808
Gene Symbol: FDPS
3 Cross references
267 Possible Orthologues:

Farnesyl-Diphosphate Farnesyltransferase 1

Ensembl ID : ENSLCRG00005009578
Gene Symbol: FDFT1
3 Cross references
220 Possible Orthologues:

Farnesyltransferase, Caax Box, Alpha

Ensembl ID : ENSLCRG00005005212
Gene Symbol: FNTA
3 Cross references
221 Possible Orthologues:

Farnesyltransferase, Caax Box, Beta

Ensembl ID : ENSLCRG00005018149
Gene Symbol: FNTB
3 Cross references
209 Possible Orthologues:

Fibroblast Growth Factor Receptor 1

Ensembl ID : ENSLCRG00005005221
Gene Symbol: FGFR1
3 Cross references
204 Possible Orthologues:

Fibroblast Growth Factor Receptor 1a

Ensembl ID : ENSLCRG00005008386
Gene Symbol: FGFR1A
3 Cross references
209 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSLCRG00005023758
Gene Symbol: FGFR2
3 Cross references
214 Possible Orthologues:

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSLCRG00005010056
Gene Symbol: FGFR3
3 Cross references
192 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSLCRG00005023197
Gene Symbol: FLT1
3 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).